RGCNasdaqMedicinal Chemicals & Botanical Products

Regencell Bioscience Holdings Ltd

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026

$10.05+0.46 (+4.80%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Regencell Bioscience Holdings Ltd income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30
Research & Development	1.30	0.95	1.07	1.58	2.51	0.44	0.39	0.23
Selling, General & Admin	10	2.82	3.67	4.69	5.11	0.94	0.43	0.16
Selling & Marketing	0.01	0.01	0.13	0.26	0.03	0.00	0.11	0.00
General & Administrative	10	2.81	3.55	4.43	5.08	0.94	0.31	0.16
Advertising Expenses	–	–	0.00	0.03	0.03	–	–	–
Operating Expenses	12	3.77	4.74	6.27	7.62	1.38	0.81	0.39
Operating Income	-12	-3.77	-4.74	-6.27	-7.62	-1.38	-0.81	-0.39
Interest & Investment Income	0.02	0.19	0.25	0.09	0.01	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	0.00	–	–	–	–
Pretax Income	-12	-3.58	-4.36	-6.06	-7.59	-1.35	-0.81	-0.39
Net Income incl. Noncontrolling Interests	-12	-3.58	-4.36	-6.06	-7.59	-1.35	-0.81	-0.39
Minority Interest in Earnings	–	–	-0.06	-0.19	-0.15	1.35	0.81	–
Net Income	-12	-3.58	-4.30	-5.87	-7.45	-1.35	-0.81	-0.39
Net Income to Common	–	–	–	-5.96	-7.45	-1.35	0.81	–
EPS (Basic)(per share)	-2.37	-0.72	-0.87	-1.19	-0.02	0.0034	0.0021	–
EPS (Diluted)(per share)	-2.37	-0.72	-0.87	-1.19	-0.02	-0.0034	-0.0021	–
Shares Outstanding (Basic, Weighted)(shares)	495	494	494	494	487	380	380	0.00
Shares Outstanding (Diluted, Weighted)(shares)	495	494	494	494	487	380	380	380

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -128.5%

Financial strength

Current ratio: 10.77
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1074.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –